Vytrus Biotech, S.A. (BME:VYT)

Spain flag Spain · Delayed Price · Currency is EUR
19.50
-0.25 (-1.27%)
At close: Apr 28, 2026
509.38%
Market Cap 146.57M
Revenue (ttm) 9.69M
Net Income (ttm) 2.90M
Shares Out 7.52M
EPS (ttm) 0.39
PE Ratio 50.60
Forward PE 40.86
Dividend n/a
Ex-Dividend Date n/a
Volume 16,649
Average Volume 14,047
Open 19.65
Previous Close 19.75
Day's Range 19.35 - 19.70
52-Week Range 3.04 - 20.60
Beta -0.14
RSI 65.33
Earnings Date Apr 9, 2026

About Vytrus Biotech

Vytrus Biotech, S.A. develops, produces, and sells active ingredients from plant stem cells in Spain and internationally. It offers Clarivine that activates skin’s regeneration processes; Quora Noni biomics for rejuvenating the skin microbiota; Deobiome Noni, a prebiotic deodorant to reduce the generation of body odour; Sarcoslim Re-Shape, an active ingredient to reduce fat on tissue; Capilia Longa that improves density in hair, eyebrows, and eyelashes; and Luminia Granatum that brightens skin, whitens dark spots, evens skin tone, and protects ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 44
Stock Exchange Madrid Stock Exchange
Ticker Symbol VYT
Full Company Profile

Financial Performance

In 2025, Vytrus Biotech's revenue was 9.69 million, an increase of 59.15% compared to the previous year's 6.09 million. Earnings were 2.90 million, an increase of 183.70%.

Financial Statements

News

There is no news available yet.